Sharechat Logo

High-flying A2 Corp to split and list on exchanges

Friday 9th February 2001

Text too small?
By Chris Hutching

Dunedin-based bio-science company A2 Corporation chief executive David Parker says the company is well advanced with its plans for a stock exchange listing in New Zealand and Australia following a $12 million share placement.

The placement of six million shares at $2 each was made to overseas shareholders who Mr Parker described as "wealthy influential individuals" who will be strategically important when the company opens offices in the US and Europe soon.

The placement allowed the company to pay $8 million for a half-share of a 1994 patent owned by the Child Health Research Foundation, with the New Zealand Dairy Board holding the other half.

The dual listing on the New Zealand and Australian stock exchanges will be preceded by a 1:4 share split to create more liquidity on February 15. The seldom-traded shares are listed by stockbrokers, with last trades at $3.20 (the shares were issued last year at $1 and have gone as high as $4).

A 35% stake in the 20 million shares currently on issue is owned by researcher Corran McLachlan and 10% by Southern Capital, with smaller stakes held by a range of shareholders including the founder of both companies, Dunedin millionaire Howard Paterson.

The company owns patents to market milk with A2 protein as opposed to milk with A1 protein that Mr McLachlan's research indicates may have a link with heart disease.

Mr Parker said A2 would make its money from royalties on a DNA testing kit that will sell for $22 a cow and from royalties on the milk itself. About a third of the New Zealand dairy herd has the A2 protein and some cows have a mixture.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report